TARA-002

Phase 3Biologic

TARA-002 is one of 20 biologic programs targeting Bladder (Urothelial, Transitional Cell) Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bladder (urothelial, Transitional Cell) CancerRecruiting

Non Muscle Invasive Bladder CancerRecruiting

Lymphatic MalformationRecruiting

Bladder (urothelial, Transitional Cell) CancerPhase 3

Recruiting

Non Muscle Invasive Bladder CancerPhase 2

Recruiting

Lymphatic MalformationPhase 2

Recruiting

Competition

Competitive Landscape

17 competitors in Non Muscle Invasive Bladder Cancer

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

3 2

Taxotere

AAvyxa

Phase 3

3 3

Bacillus Calmette-Guerin

AstraZeneca

Phase 3

2 4

Disitamab Vedotin

Pfizer

Phase 2

1 5

Cretostimogene Grenadenorepvec

CCG Oncology, Inc.

Phase 3

3 6

Nadofaragene Firadenovec

Ferring

Phase 3

2 7

TARA-002

PProtara Therapeutics

Phase 3

1 8

Trodelvy

Gilead

Preclinical

1 9

Gemcitabin

GGerman Cancer Research Center

Phase 2

1 10

Theracys® BCG

FFudan University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Lymphatic Malformation

NCT05871970

Q1 2032

Phase 2Recruiting

Non Muscle Invasive Bladder Cancer

NCT05951179

Q4 2032

Phase 3Recruiting

Bladder (urothelial, Transitional Cell) Cancer

NCT07480356

Clinical

Trials by Indication[1]

Bladder Cancer2 trials

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

Completed·PProtara Therapeutics·Phase 1·NCT05085977·12 enrolled

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)

Completed·PProtara Therapeutics·Phase 1·NCT05085990·10 enrolled

Lymphatic Malformation1 trial

A Phase 2a/b Single Arm Open Label Study to Evaluate the Safety and Efficacy of Intracystic Administration of TARA-002 in Participants Between 6 Months to Less Than 18 Years of Age for the Treatment of Macrocystic and Mixed Cystic Lymphatic Malformations

Recruiting·PProtara Therapeutics·Phase 2·NCT05871970·38 enrolled

Non Muscle Invasive Bladder Cancer1 trial

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer

Recruiting·PProtara Therapeutics·Phase 2·NCT05951179·131 enrolled

Bladder (Urothelial, Transitional Cell) Cancer1 trial

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-Grade Non-Muscle Invasive Bladder Cancer

Recruiting·PProtara Therapeutics·Phase 3·NCT07480356·284 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for TARA-002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TARA-002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TARA-002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Protara Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: PProtara Therapeutics

TARA-002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2032

Q4 2032

Trials by Indication[1]

Bladder Cancer2 trials

Lymphatic Malformation1 trial

Non Muscle Invasive Bladder Cancer1 trial

Bladder (Urothelial, Transitional Cell) Cancer1 trial

References

Drug Info

Quick Facts

Related News